(Q36360551)

13 August 2017

1 reference

title

Review article: Drug therapy for non-alcoholic fatty liver disease (English)

1 reference

non-alcoholic fatty liver

13 August 2017

1 reference

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

Comar KM

1

1 reference

PubMed ID

16393299

13 August 2017

Sterling RK

series ordinal

2

1 reference

PubMed ID

16393299

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Alimentary Pharmacology & Therapeutics

13 August 2017

1 reference

13 August 2017

23

1 reference

13 August 2017

2

1 reference

13 August 2017

207-215

1 reference

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

The natural history of nonalcoholic fatty liver: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

The clinicopathologic spectrum and management of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Clinical features and natural history of nonalcoholic steatosis syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

AGA technical review on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Etiopathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Fatty liver, hypertension, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Evaluation and management of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Diagnosis of fatty liver disease: is biopsy necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Liver pathology and the metabolic syndrome X in severe obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Association of nonalcoholic fatty liver disease with insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Cytokines in alcoholic and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Tumour necrosis factor alpha: a key regulator of adipose tissue mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Antioxidative properties of probucol estimated by the reactivity with superoxide and by electrochemical oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02751.X

10.1111/J.1365-2036.2006.02751.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16393299